EIF4E and neoplasm: In the phase I clinical trial, LY2275796 was tested in multiple advanced cancers including melanoma, and while administration of LY2275796 at 1000 mg/kg was well-tolerated and was effective at decreasing overall eIF4E levels in tissues, no tumor response was observed [115].